LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
| Price | $4.09 |
|---|---|
| Market cap | $128.08M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
| 52-week range | 4.01-50.4 |
| Beta | 1.63 |
Explore LENZ's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.